Cargando…

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma

Homologous recombination repair (HRR) pathway deficiency (HRD) is involved in the tumorigenesis and progression of high-grade serous ovarian carcinoma (HGSOC) as well as in the sensitivity to platinum chemotherapy drugs. In this study, we obtained data from The Cancer Genome Atlas (TCGA) on HGSOC an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takaya, Hisamitsu, Nakai, Hidekatsu, Takamatsu, Shiro, Mandai, Masaki, Matsumura, Noriomi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026096/ https://www.ncbi.nlm.nih.gov/pubmed/32066851 http://dx.doi.org/10.1038/s41598-020-59671-3

Ejemplares similares

Histopathological subtyping of high-grade serous ovarian cancer using whole slide imaging
por: Miyagawa, Chiho, et al.
Publicado: (2023)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2021)

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for Ovarian Cancer
por: Takamatsu, Shiro, et al.
Publicado: (2023)

Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor
por: Nakai, Hidekatsu, et al.
Publicado: (2019)

Superparamagnetic iron oxide as a tracer for sentinel lymph node detection in uterine cancer: a pilot study
por: Murakami, Kosuke, et al.
Publicado: (2020)

Recurrence of uterine myoma after myomectomy: Open myomectomy versus laparoscopic myomectomy
por: Kotani, Yasushi, et al.
Publicado: (2017)

Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020)

Measures for Safe Laparoscopic Sacrocolpopexy: Preoperative Contrast-Enhanced Computed Tomography and Perioperative Ultrasonography
por: Kotani, Yasushi, et al.
Publicado: (2021)

Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics
por: Konishi, Ikuo, et al.
Publicado: (2022)

Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma
por: Murakami, Kosuke, et al.
Publicado: (2021)

Progression after discontinuation of bevacizumab in the first-line treatment of ovarian cancer
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
por: Nakai, Hidekatsu, et al.
Publicado: (2022)

Treatment for Locally Resectable Stage IIIC1 Cervical Cancer: A Retrospective, Single-Institution Study
por: Kashima, Yoko, et al.
Publicado: (2023)

Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)
por: Nakai, Hidekatsu, et al.
Publicado: (2023)

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes
por: Sohn, Min-Hwan, et al.
Publicado: (2021)

Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma Using Magnetic Resonance Images: A Literature Review
por: Suzuki, Ayako, et al.
Publicado: (2019)

Correction to: Quality of life after laparoscopic hysterectomy versus abdominal hysterectomy
por: Kotani, Yasushi, et al.
Publicado: (2021)

Research Article Quality of life after laparoscopic hysterectomy versus abdominal hysterectomy
por: Kotani, Yasushi, et al.
Publicado: (2021)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
por: Feng, Zheng, et al.
Publicado: (2023)

Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy
por: Murakami, Kosuke, et al.
Publicado: (2020)

Homologous recombination inquiry through ovarian malignancy investigations: JGOG3025 Study
por: Yoshihara, Kosuke, et al.
Publicado: (2023)

Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
por: Su, Rongjia, et al.
Publicado: (2021)

A Benchmark of In-House Homologous Recombination Repair Deficiency Testing Solutions for High-Grade Serous Ovarian Cancer Diagnosis
por: Guarischi-Sousa, Rodrigo, et al.
Publicado: (2023)

CXCL13-producing CD4(+) T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer
por: Ukita, Masayo, et al.
Publicado: (2022)

Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer
por: van Wagensveld, Lilian, et al.
Publicado: (2022)

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma
por: Shi, Zhiwen, et al.
Publicado: (2021)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells
por: Gomez, Miriam K., et al.
Publicado: (2020)

RAD51 as a biomarker for homologous recombination deficiency in high‐grade serous ovarian carcinoma: robustness and interobserver variability of the RAD51 test
por: Kramer, Claire JH, et al.
Publicado: (2023)

Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma
por: Choi, Min Chul, et al.
Publicado: (2020)

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors
por: Lu, Xue, et al.
Publicado: (2022)

Epigenetic and genetic dispositions of ovarian carcinomas
por: Yamaguchi, Ken, et al.
Publicado: (2014)

TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
por: Chien, Jeremy, et al.
Publicado: (2015)

Homologous recombination repair gene mutations show no survival benefits in Chinese high-grade serous ovarian cancer patients
por: Feng, Zheng, et al.
Publicado: (2021)

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
por: Pikkusaari, Sanna, et al.
Publicado: (2023)

Development of Serous Ovarian Cancer is Associated with the Expression of Homologous Recombination Pathway Proteins
por: Ye, Qingqing, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vtudlpp6ac1neuulpoemur3iq4